| ↑ | upregulation |
| ↓ | downregulation |
| 5-FU | 5-fluorouracil |
| ABC | ATP-binding cassette transporter proteins |
| ABCB1, ABCG1 | isoforms of ATP-binding cassette transporter proteins |
| ARE | antioxidant response element |
| ABT-263 | small molecule that inhibits Bcl-2; 4-(4-{[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl}c-1-piperazinyl)-N-[(4-{[(2R)-4-(4-morpholinyl)-1-(phenylsulfanyl)-2-butanyl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide |
| ABT-737 | small molecule that inhibits Bcl-2; 4-{4-[(4′-Chloro-2-biphenylyl)methyl]-1-piperazinyl}-N-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)-2-butanyl]amino}-3-nitrophenyl)sulfonyl]benzamide |
| AKT | protein kinase B |
| ALDH | aldehyde dehydrogenase |
| ALP | autophagy lysosomes systems |
| AMPK | AMP-activated protein kinase |
| APAF1 | apoptotic protease activating factor 1 |
| APR-246 | drug that binds to p53 (restoring p53 function) and depletes glutathione; PRIMA-1, 2-hydroxymethyl-2-methoxymethyl-aza-bicyclo[2.2.2]octan-3-one |
| AR | androgen receptor |
| ATR | serine/threonine protein kinase |
| Axl, Tyro3 | receptors for tyrosine kinase |
| BASE | base excision repair |
| Bax | Bcl-2-associated X protein/Bcl-2-like protein 4 |
| Bcl-2 | B cell lymphoma 2 protein |
| Bcl-XL | B cell lymphoma extra-large protein |
| BCRA1, 2 | breast cancer susceptible genes |
| BCRP | breast cancer resistant protein |
| BER | base excision repair |
| BH | Bcl-2 homology domain |
| BIM | Bcl-2 like protein 11 |
| BNDQ | quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles |
| BPIS | bound polyphenols of inner shell from foxtail millet bran |
| BRAF | serine/threonine-protein kinase B-Raf |
| C | catechin |
| CAB | carboplatin |
| CAPE | caffeic acid phenethyl ester |
| CAR | constitutive androstane receptor |
| caspase-3, 8, 9 | cysteine aspartic proteases-3, 8, 9 |
| CBZ | cabazitaxel |
| CD44, 24, 133 | cluster of differentiation 44, 24, 133 |
| CDF | difluorinated curcumin |
| CDK 2,4,6 | cyclin-dependent kinases 2,4,6 |
| CDPP | cisplatin |
| CEA | carcioembryonic antigen |
| cFLIP | regulator of caspase-8 activation; cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein |
| CgA | chromogranin |
| Chk1/2 | Check point kinase 1/2 |
| cIAP-1,2 | cellular inhibitor of apoptosis protein 1,2 |
| COMT | catechol-O-methyl transferase |
| COX-2 | ciclo-oxygenase 2 |
| CPT11 | irinotecan |
| CREB-1 | element binding protein-1 |
| CRPC | castration-resistant prostate cancer |
| CSC | cancer stem cells |
| CXCR4 | CXC chemokine receptor type 4 |
| CYP1A1, CYP1B1, CYP19A1, CYP17A1 | isoforms of cytochrome 450 |
| CYP3A4 | cytochrome P450 3A4 |
| DDR | DNA damage response |
| DIABLO | direct IAP-binding protein with Low pI |
| DMBA | 7,12-dimethylbenz[a] anthracene |
| DNA | deoxyribonucleic acid |
| DOC | docetaxel |
| DOX | doxorubicin (adriamycin) |
| DPPT | deoxypodophyllotoxin |
| DR4/5 | pro-apoptotic death receptors |
| EC | epicatechin |
| EGC | epigallocatechin |
| EGCG | epigallocatechingallate |
| EGF | epidermal growth factor |
| EGFR | epithelial growth factor receptor |
| EGFR(T790M) | epithelial growth factor receptor with a mutation that replace threonine by methionine at position 790 |
| EGR-1 | early growth response protein 1 |
| EMT | epithelial-mesenchymal transition |
| ENL | enterolactone |
| ER | estrogen receptors |
| ERα/ERβ | estrogen receptor alpha/estrogen receptor beta |
| ERK 1,2 | extracellular-signal regulated kinase |
| ETS2 | proto-oncogene 2, transcription factor (v-ets, Avian Erythroblastosis Virus E26 Oncogene Homolog 2) |
| EZH2 | enhancer of zeste homolog 2 (histone methyltransferase) |
| FASN | fatty acid synthase |
| FBAP5 | fatty acid-binding protein 5 |
| FGF | fibroblast growth factor |
| FOLFOX | 5-fluorouracil, oxaliplatin, folinic acid |
| GF | gefitinib |
| GRP78 | glucose regulated protein |
| GSH | reduced glutathione |
| GSK3 | glycogen synthase kinase 3 |
| GST | glutathione-S transferase |
| GPX | glutathione peroxidase |
| GTE | green tea extract |
| HER-2, 3 | human epidermal growth factor 2, 3 |
| Her2/neu | receptor tyrosine-proteinkinase erbB-2 |
| HGFR/MET | hepatocyte growth factor receptor |
| HIF-1α | hypoxia-inducible factor 1 alpha |
| hMLH1 | mismatch repair gene of human mutL homolog 1 |
| HNK | honokiol |
| HO-1 | hemeoxygenase 1 |
| HR | homologous recombination |
| HRas | transforming protein p21 |
| IAP | inhibitors of apoptosis proteins |
| ICAM-1 | intercellular adhesion molecule 1 |
| IGF-1R | insulin growth factor receptor |
| IL-6, 8, 17, 18 | interleukin-6, 8, 17, 18 |
| i.p. | intraperitoneal administration |
| i.v | intravenous administration |
| JNK | c-Jun N-terminal kinase |
| Keap 1 | kelch-like ECH-associated protein 1 |
| KRAS | gene identified in Kirsten rat sarcoma |
| MAPK | mitogen activated protein kinase |
| MDM2 | mouse double minute 2 homolog |
| MDR | multidrug resistance |
| Meriva | turmeric/phospholipid formulation |
| MET | tyrosine-proteinkinase |
| MLH1,2 | human mutL homolog 1,2 |
| MMP | mitochondrial membrane potential |
| MMP-2,9 | metalloproteinases 2,9 |
| MMR | mismatch repair |
| MRP1/2 | multidrug resistance associated protein 1/2 |
| mRNA | messenger RNA |
| miRNA | microRNA |
| miR-16, 17, 21, 200c, 17-5p, 892c | microRNA-16, 17, 21, 200c, 17-5p, 892c |
| MSH 1/2 | DNA mismatch repair protein 1/2 |
| mTOR | mammalian target of rapamycin |
| NAD(P)H | reduced nicotinamide adenine dinucleotide phosphate |
| NER | nucleotide excision repair |
| NF-κB | nuclear factor kappa-light-chain-enhancer of activated B cells |
| NGF | nerve growth factor |
| NHEJ | non-homologous end-joining |
| NOX | NADPH oxidases |
| NPs | nanoparticles |
| Nrf2 | erythroid 2-related factor 2 |
| NSCLC | non-small cell lung cancer |
| NSE | neurospecific enolase |
| OX | oxaliplatin |
| p53 | tumor suppressor protein |
| P-gp (MDR1) | P-glycoprotein (multidrug resistance protein 1) |
| PI3K/AKT | phosphoinositide 3-kinase/protein kinase B |
| PKC | proteinkinase C |
| p.o. | oral administration |
| PPARβ/δ | peroxisome proliferator-activated receptor β/δ |
| PPT | podophyllotoxin |
| PS | phospho-sulindac |
| PSA | prostate serum antigen |
| PTEN | phosphatase and tensin homolog |
| PTX | paclitaxel |
| PXR | pregnane X receptor |
| RARs | retinoic acid receptors |
| RES | resveratrol |
| ROS | reactive oxygen species |
| SCC | squamous cell carcinoma |
| SChA | schizandrin A |
| SCLC | small cell lung cancer |
| SECO | secoisolariciresinol |
| Smac | second mitochondria-derived activator of caspase |
| SOD | superoxide-dismutase |
| Src | proto-oncogene tyrosine-protein kinase |
| SRT501 | small molecule, a form of resveratrol designed to target sirtuin 1 protein |
| STAT3 | signal transducer and activator of transcription 3 |
| T-box 3 | T-box transcription factor 3 |
| Tf-PEG-CUR | transferrin-poly(ethylene glycol)-curcumin |
| TGF-β | transforming growth factor |
| TKI | tyrosine kinase inhibitors |
| TME | tumor microenvironment |
| TP53 | gene coding tumor suppressor protein p53 |
| TRAIL | TNF-related apoptosis-inducing ligand |
| UGT | uridine diphospho-glucuronosyltransferase |
| VCR | vincristine |
| VEGF | vascular endothelial growth factor |
| VEGFR2 | vascular endothelial growth factor receptor 2 |
| Wnt/β-catenin | wingless-type MMTV integration site family member (MMTV, mouse mammary tumor virus)/beta-catenin signaling pathway |
| xCT | glutamate cysteine antiporter |
| XIAP | X-linked inhibitor of apoptosis protein |
| YB-1 | Y-box binding protein-1 |